On June 30, 2023 Sinocell Engineering Co., Ltd. ("Sinocell") reported that the National Medical Products Administration (NMPA) has officially approved the marketing application for the company’s independently developed bevacizumab injection, Ambezu (Press release, Sinocelltech, JUN 30, 2023, View Source [SID1234656254]). The approval of Ambezu further enriches the company’s commercialized product pipeline in the oncology field, bringing high-quality, affordable treatment options to more patients in China and contributing to the development of the Chinese pharmaceutical industry.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Anbezumab is a recombinant humanized anti-VEGF monoclonal antibody injection independently developed by the company . It is a biosimilar to bevacizumab injection (Avastin). The approved indications include metastatic colorectal cancer, advanced, metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, hepatocellular carcinoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and cervical cancer.

Specific VEGF-targeted antibody drugs can reduce angiogenesis within tumors by blocking the binding of free VEGF to VEGF receptors (VEGFRs), thereby causing tumor tissue to lose the nutritional environment required for survival and proliferation and improving the tumor immune activation environment.